ChemomAb’s CM-101 Receives FDA Clearance for Phase 2 trial in Adults with Systemic Sclerosis (SSc)
ChemomAb Ltd. has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) Application to assess CM-101 in a Phase 2 trial for systemic sclerosis (SSc ...